VTRS
Viatris Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+52/100
Last price
17.64
▲ 0.02 (0.12%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
17.62
Prev close
17.62
Day high
17.87
Day low
17.31
Volume
6.68M
Market cap
$20.15B
P/E (TTM)
—
52W range
9.69 – 18.43
Day trading desk
Gap from prior close
-0.00%
Prior close 17.62
VWAP
17.55
+0.51% from price
Relative volume
1.25×
Normal
Session range
18.75%
16.00 – 19.00
Position in range
55%
Mid range
ATR (14D)
0.47
2.66% of price
Prior day high
17.91
PDH
Prior day low
17.45
PDL
Bid / ask spread
—
Quote not published
Session volume
11.53M
Avg 9.20M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.20%
-5.1%
1M
+3.91%
+2.8%
3M
+5.28%
+0.8%
6M
+33.28%
+15.1%
YTD
+40.88%
+26.6%
1Y
+72.13%
+55.7%
3Y
+77.89%
-4.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on VTRS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+19.05K
Net buying
Buy transactions
2
69.12K shares
Sell transactions
1
50.08K shares
Net transactions
+3
Buys less sells
Sell : buy shares
0.7 : 1
Mixed
Insider-held shares
3.65M
Total on file
Fundamentals
Market cap$20.15B
Enterprise value$32.26B
Revenue (TTM)$14.74B
Gross profit$5.94B
EBITDA$4.29B
Net income$-410.70M
EPS (TTM)$-0.36
Free cash flow$2.68B
Total cash$1.51B
Total debt$13.62B
Book value / share$12.59
Shares outstanding1.15B
Float1.14B
Short % of float3.56%
Dividend yield2.72%
Beta (5Y)0.86
Valuation & profitability ratios
Trailing P/E—
Forward P/E6.56
PEG ratio3.20
Price / sales—
Price / book1.39
EV / revenue2.19
EV / EBITDA7.52
Gross margin40.31%
Operating margin12.55%
Profit margin-2.79%
Return on equity-2.75%
Return on assets2.67%
Debt / equity95.54
Current ratio1.59
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $14.30B | $14.74B | $15.43B | $16.26B | -3.0% |
| Operating revenue | $23.73B | $24.91B | $25.69B | $27.66B | -4.7% |
| Cost of revenue | $9.29B | $9.12B | $8.99B | $9.77B | +1.9% |
| Gross profit | $5.01B | $5.62B | $6.44B | $6.50B | -10.8% |
| Research & development | $965.90M | $808.70M | $805.20M | $662.20M | +19.4% |
| Selling, general & admin | $3.79B | $4.10B | $4.07B | $4.18B | -7.6% |
| Total operating expense | $4.76B | $4.91B | $4.88B | $4.84B | -3.1% |
| Operating income | $253.50M | $710.30M | $1.56B | $1.66B | -64.3% |
| Net interest income | -$471.30M | -$550.00M | -$573.10M | -$592.40M | +14.3% |
| Pre-tax income | -$3.67B | -$623.20M | $202.90M | $2.81B | -488.1% |
| Tax provision | -$150.10M | $11.00M | $148.20M | $734.60M | -1,464.5% |
| Net income | -$3.51B | -$634.20M | $54.70M | $2.08B | -454.2% |
| Net income to common | -$3.51B | -$634.20M | $54.70M | $2.08B | -454.2% |
| Basic EPS | -3.00 | -0.53 | 0.05 | 1.71 | -466.0% |
| Diluted EPS | -3.00 | -0.53 | 0.05 | 1.71 | -466.0% |
| EBIT | -$3.19B | -$73.20M | $776.00M | $3.41B | -4,263.0% |
| EBITDA | -$395.40M | $2.82B | $3.52B | $6.43B | -114.0% |
| Basic shares | 1.17B | 1.19B | 1.20B | 1.21B | -1.9% |
| Diluted shares | 1.17B | 1.19B | 1.21B | 1.22B | -1.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.32B | $734.80M | $991.90M | $1.26B | +80.0% |
| Cash & short-term investments | $1.51B | $1.09B | $1.18B | $1.47B | +38.8% |
| Accounts receivable | $2.58B | $2.68B | $2.82B | $3.24B | -3.7% |
| Inventory | $4.00B | $3.85B | $3.47B | $3.52B | +3.8% |
| Total current assets | $9.79B | $9.52B | $12.98B | $10.64B | +2.8% |
| Property, plant & equipment | $2.89B | $2.92B | $3.01B | $3.28B | -1.2% |
| Goodwill & intangibles | $21.86B | $26.20B | $29.05B | $33.03B | -16.6% |
| Total assets | $37.19B | $41.50B | $47.69B | $50.02B | -10.4% |
| Total current liabilities | $7.09B | $5.78B | $7.78B | $6.75B | +22.8% |
| Current debt | $1.93B | $600.00K | $1.93B | $1.25B | +321,550.0% |
| Long-term debt | $12.48B | $14.04B | $16.19B | $18.02B | -11.1% |
| Total debt | $14.70B | $14.31B | $18.37B | $19.53B | +2.7% |
| Total liabilities | $22.48B | $22.87B | $27.22B | $28.95B | -1.7% |
| Retained earnings | -$388.30M | $3.42B | $4.64B | $5.18B | -111.4% |
| Shareholder equity | $14.71B | $18.64B | $20.47B | $21.07B | -21.1% |
| Working capital | $2.69B | $3.74B | $5.20B | $3.89B | -28.0% |
| Net tangible assets | -$7.15B | -$7.57B | -$8.58B | -$11.96B | +5.6% |
| Shares issued | 1.25B | 1.23B | 1.22B | 1.21B | +0.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$3.51B | -$634.20M | $54.70M | $2.08B | -454.2% |
| Depreciation & amortisation | $2.80B | $2.89B | $2.74B | $3.03B | -3.3% |
| Stock-based compensation | $177.70M | $146.10M | $180.70M | $116.40M | +21.6% |
| Change in working capital | -$686.40M | -$318.60M | -$711.30M | -$922.60M | -115.4% |
| Operating cash flow | $2.32B | $2.30B | $2.90B | $3.00B | +0.6% |
| Capital expenditure | -$465.10M | -$359.10M | -$574.90M | -$489.40M | -29.5% |
| Investing cash flow | -$427.70M | $1.80B | -$864.50M | $1.47B | -123.8% |
| Share buybacks | -$500.50M | -$250.00M | -$250.00M | $0 | -100.2% |
| Dividends paid | -$561.20M | -$574.80M | -$575.60M | -$581.60M | +2.4% |
| Financing cash flow | -$1.29B | -$4.33B | -$2.30B | -$3.88B | +70.1% |
| Free cash flow | $1.85B | $1.94B | $2.33B | $2.51B | -4.8% |
| End cash position | $1.35B | $736.10M | $993.60M | $1.26B | +83.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $3.76B | $3.52B | $3.70B | $3.76B | $3.58B | +6.8% |
| Operating revenue | $6.08B | $5.92B | $5.98B | $6.21B | $5.97B | +2.6% |
| Cost of revenue | $2.30B | $2.36B | $2.56B | $2.39B | $2.25B | -2.5% |
| Gross profit | $1.46B | $1.16B | $1.15B | $1.37B | $1.33B | +25.9% |
| Research & development | $248.30M | $248.60M | $274.70M | $250.40M | $218.80M | -0.1% |
| Selling, general & admin | $1.13B | $928.80M | $1.03B | $886.60M | $928.70M | +22.1% |
| Total operating expense | $1.38B | $1.18B | $1.31B | $1.14B | $1.15B | +17.4% |
| Operating income | $73.70M | -$20.20M | -$157.50M | $234.50M | $185.40M | +464.9% |
| Net interest income | -$120.70M | -$120.10M | -$119.60M | -$119.60M | -$116.60M | -0.5% |
| Pre-tax income | -$64.00M | -$247.30M | -$343.00M | -$7.90M | -$217.10M | +74.1% |
| Tax provision | $54.80M | -$423.70M | -$2.90M | $120.30M | -$212.50M | +112.9% |
| Net income | -$118.80M | $176.40M | -$340.10M | -$128.20M | -$4.60M | -167.3% |
| Net income to common | -$118.80M | $176.40M | -$340.10M | -$128.20M | -$4.60M | -167.3% |
| Basic EPS | -0.10 | 0.15 | -0.30 | -0.11 | 0.00 | -166.7% |
| Diluted EPS | -0.10 | 0.15 | -0.30 | -0.11 | 0.00 | -166.7% |
| EBIT | $56.70M | -$127.20M | -$223.40M | $111.70M | -$100.50M | +144.6% |
| EBITDA | $729.00M | $548.90M | $543.40M | $800.20M | $577.80M | +32.8% |
| Basic shares | 1.16B | 1.16B | 1.15B | 1.16B | 1.17B | +0.7% |
| Diluted shares | 1.16B | 1.18B | 1.15B | 1.16B | 1.17B | -1.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $886.50M | $1.80B | $1.32B | $975.30M | $566.40M | -50.9% |
| Cash & short-term investments | $1.51B | $2.40B | $1.51B | $1.16B | $808.60M | -37.1% |
| Accounts receivable | $2.58B | $2.58B | $2.58B | $2.91B | $2.79B | +0.1% |
| Inventory | $3.93B | $3.93B | $4.00B | $4.11B | $4.26B | +0.2% |
| Total current assets | $10.06B | $10.92B | $9.79B | $9.95B | $9.77B | -7.9% |
| Property, plant & equipment | $2.70B | $2.78B | $2.89B | $2.89B | $2.92B | -3.0% |
| Goodwill & intangibles | $20.33B | $21.17B | $21.86B | $22.45B | $23.07B | -4.0% |
| Total assets | $35.04B | $36.83B | $37.19B | $37.92B | $38.41B | -4.9% |
| Total current liabilities | $6.35B | $6.81B | $7.09B | $7.36B | $7.13B | -6.8% |
| Current debt | $1.74B | $1.93B | $1.93B | $1.94B | $1.67B | -9.8% |
| Long-term debt | $11.61B | $12.41B | $12.48B | $12.49B | $12.79B | -6.5% |
| Total debt | $13.63B | $14.61B | $14.70B | $14.72B | $14.76B | -6.7% |
| Total liabilities | $20.78B | $22.18B | $22.48B | $22.70B | $22.84B | -6.3% |
| Retained earnings | -$330.70M | -$211.90M | -$388.30M | -$48.20M | $80.00M | -56.1% |
| Shareholder equity | $14.26B | $14.66B | $14.71B | $15.22B | $15.57B | -2.7% |
| Working capital | $3.71B | $4.11B | $2.69B | $2.59B | $2.64B | -9.7% |
| Net tangible assets | -$6.07B | -$6.52B | -$7.15B | -$7.24B | -$7.50B | +6.8% |
| Shares issued | 1.16B | 1.26B | 1.25B | 1.25B | 1.25B | -8.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$118.80M | $176.40M | -$340.10M | -$128.20M | -$4.60M | -167.3% |
| Depreciation & amortisation | $672.30M | $676.10M | $766.80M | $688.50M | $678.30M | -0.6% |
| Stock-based compensation | $38.70M | $48.20M | $49.40M | $36.00M | $37.10M | -19.7% |
| Change in working capital | -$347.30M | -$702.90M | $391.80M | $126.00M | -$982.30M | +50.6% |
| Operating cash flow | $381.80M | $388.30M | $815.80M | $744.90M | $219.70M | -1.7% |
| Capital expenditure | -$59.80M | -$124.20M | -$234.90M | -$99.70M | -$54.10M | +51.9% |
| Investing cash flow | -$51.60M | $277.40M | -$211.20M | -$98.90M | -$52.50M | -118.6% |
| Share buybacks | -$150.00M | $0 | -$85.10M | -$65.00M | -$175.00M | — |
| Dividends paid | -$139.80M | -$139.60M | -$138.20M | -$139.90M | -$139.80M | -0.1% |
| Financing cash flow | -$1.24B | -$203.80M | -$236.40M | -$228.10M | -$362.40M | -509.7% |
| Free cash flow | $322.00M | $264.10M | $580.90M | $645.20M | $165.60M | +21.9% |
| End cash position | $890.00M | $1.81B | $1.35B | $1.00B | $567.80M | -50.7% |
Options analytics
Put / call volume
0.30
Call-heavy session
Put / call open interest
0.30
Positioning, not flow
Max pain
16.00
-8.8% from spot
ATM implied vol
37.7%
Nearest strike to spot
Skew (10% OTM)
+5.9%
Puts bid over calls
Call volume
307
Contracts, this expiry
Put volume
93
Contracts, this expiry
Heaviest call OI
19.00
3.65K contracts
Heaviest put OI
15.00
1.11K contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 0.60 | 0.69 | +15.0% |
| Mar 2026 | 0.50 | 0.59 | +17.5% |
| Dec 2025 | 0.53 | 0.57 | +7.4% |
| Sep 2025 | 0.62 | 0.67 | +8.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 0.64 | 10 | $3.80B | +1.0% |
| Next quarter | 0.59 | 10 | $3.72B | +0.3% |
| Current year | 2.52 | 11 | $14.79B | +3.4% |
| Next year | 2.67 | 11 | $15.04B | +1.7% |
Analyst targets & ownership
Mean target$19.70
High target$26.00
Low target$13.00
Implied upside11.67%
Analyst count10
ConsensusBUY
Strong buy / Buy1 / 6
Hold4
Sell / Strong sell0 / 1
Held by insiders0.32%
Held by institutions93.67%
Institutions holding1.37K
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
17.67
-0.16% from price
SMA 20
17.24
+1.75% from price
SMA 50
16.95
+3.48% from price
SMA 100
16.67
+5.84% from price
SMA 200
15.38
+14.06% from price
EMA 12
17.51
+0.72% from price
EMA 26
17.26
+2.23% from price
EMA 50
17.00
+3.78% from price
RSI (14)
55.9
Neutral
MACD (12,26,9)
0.26
Hist 0.01
ATR (14)
0.47
2.68% of price
Realised vol 30D
21.9%
Annualised
Bollinger upper
18.29
20, 2σ
Bollinger lower
16.19
20, 2σ
50 / 200 cross
Golden
16.95 vs 15.38
Trend bias
Above 200
+14.06%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.70
Less volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
21.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-19.7%
Peak to trough
Max drawdown 5Y
-52.9%
Peak to trough
ATR 14
0.47
2.68% of price
Beta (reported)
0.86
5Y monthly, from filing
Short interest
Shares short
40.79M
Prior 37.02M
Change vs prior
+10.2%
Shorts adding
% of float
3.56%
Normal
% of shares out
3.55%
Against total outstanding
Days to cover
5.5
Crowded exit
Float
1.14B
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | UBS | MAINTAINED | Buy | Buy |
| Sep 23, 26 | Oppenheimer | INITIATED | — | Outperform |
| Sep 16, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Sep 9, 26 | Leerink Partners | INITIATED | — | Outperform |
| Sep 8, 26 | Argus Research | MAINTAINED | Buy | Buy |
| May 19, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| May 8, 26 | JP Morgan | MAINTAINED | Neutral | Neutral |
| May 8, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Mar 24, 26 | Barclays | MAINTAINED | Overweight | Overweight |
| Jan 28, 26 | Piper Sandler | MAINTAINED | Neutral | Neutral |
| Jan 16, 26 | Argus Research | UPGRADE | Hold | Buy |
| Dec 9, 25 | Barclays | INITIATED | — | Overweight |
Dividends & splits
Forward rate$0.48 / yr
Forward yield2.72%
5-year avg yield3.88%
Payout ratio960.00%
Ex-dividend dateAug 21, 2026
Next pay dateSep 16, 2026
Last split3:2
Split dateOct 9, 2003
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-07-01
Corporate Changes & Voting Matters
8-K · 2026-06-18
Corporate Changes & Voting Matters
8-K · 2026-06-15
Corporate Changes & Voting Matters
8-K · 2026-05-15
Periodic Financial Reports
10-Q · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-05-04
Annual Report to Shareholders
ARS · 2026-04-02
Headlines
VTRS vs. AVTR: Which Stock Is the Better Value Option?
Zacks · 12h ago
Should Value Investors Buy Viatris (VTRS) Stock?
Zacks · 14h ago
UBS Adjusts Price Target on Viatris to $26 From $23, Keeps Buy Rating
MT Newswires · 2d ago
Harrow Completes Acquisition of Tyrvaya Nasal Spray From Viatris
MT Newswires · 2d ago
FDA Decision Watch: RHHBY, VTRS And IRD Face Key October Drug Rulings As MRK Withdraws Application
Stocktwits · 2d ago
Harrow Closes Acquisition of TYRVAYA®
GlobeNewswire · 2d ago
Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026
PR Newswire · 2d ago
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year
PR Newswire · 7d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.